Related Experiment Video
Updated: May 1, 2026
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Argatroban for preventing occlusion and restenosis after extracranial artery stenting
1Departments of Neurology at Jinling Hospital, Southern Medical University, Nanjing, PR China.
Insights
Argatroban, a direct thrombin inhibitor, significantly reduced restenosis after extracranial artery stenting in a pilot study. This intravenous treatment showed promising safety and efficacy, warranting larger trials for stroke prevention.
Area of Science:
- Cardiovascular Medicine
- Neurology
- Pharmacology
Background:
- Restenosis after extracranial artery stenting limits long-term outcomes.
- Effective pharmacological strategies for preventing restenosis remain elusive.
- This study investigates argatroban as a potential preventative agent.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous argatroban in preventing in-stent restenosis.
- To assess the impact of argatroban on target revascularization and adverse events.
- To provide preliminary data for larger clinical trials.
Main Methods:
- A randomized controlled trial involving 114 patients undergoing extracranial artery stenting.
- Patients received either intravenous argatroban or a placebo (control group).
- Follow-up included 12-month clinical assessment and angiographic analysis for restenosis.
Main Results:
- Restenosis occurred in 7.4% of the argatroban group versus 21.6% in the control group (p=0.032).
- A trend towards lower target revascularization was observed in the argatroban group (5.4% vs. 13.7%).
- No major bleeding or adverse events were reported with argatroban treatment.
Conclusions:
- Intravenous argatroban is effective and safe in preventing restenosis post-extracranial artery stenting.
- This pilot study provides a strong rationale for further investigation.
- Larger randomized controlled trials are recommended to confirm these findings.
Background/Aims:
Restenosis following extracranial artery stenting is a limitation that affects long-term outcomes. Effective and satisfying pharmacological strategies in preventing restenosis have not been established. This study aimed to evaluate whether argatroban, a direct thrombin inhibitor, could reduce the risk of in-stent restenosis after extracranial artery stenting.
Methods:
One hundred and fourteen patients hospitalized between August 2010 and August 2011 were enrolled. Patients were randomly assigned to argatroban (n = 58) and blank control groups (n = 56). The patients in the argatroban arm were treated with 10 mg of intravenous argatroban twice daily 2 days before and 3 days after the stenting procedures. Patients were followed for 12 months after the procedure. During follow-up, restenosis and target revascularization were analyzed. Recurrent cerebrovascular and cardiovascular events and deaths were also compared between the groups.
Results:
One patient in the stenting group withdrew immediately after the procedure due to unsuccessful stenting. Restenosis occurred in 4 patients (7.4%) in the argatroban group and in 11 patients (21.6%) in the control group during the 6- to 9-month angiographic follow-up period (p = 0.032). Nine months after the procedures, argatroban-treated patients had a trend towards a lower incidence of target revascularization compared with the controls (5.4 vs. 13.7%, p = 0.188). No major bleeding events or other adverse events occurred in the argatroban group.
Conclusion:
This pilot clinical trial is the first that uses argatroban to prevent restenosis in ischemic cerebrovascular disease, and suggests that intravenous administration of argatroban is effective and safe in preventing restenosis after extracranial artery stenting. Larger randomized controlled clinical trials are warranted.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...